Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

1. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all (...) adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.To assess the effects and safety of bupropion for the treatment of adults with ADHD.We searched

Full Text available with Trip Pro

2017 Cochrane

2. Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness

Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness (...) Published on: March 8, 2016 Project Number: RC0747-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of nicotine replacement therapy versus bupropion or varenicline in the general population of tobacco users? What is the comparative clinical effectiveness of nicotine replacement therapy, bupropion or varenicline versus placebo in the general population of tobacco users? Key Message Ten relevant

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Prolonged release naltrexone and bupropion (Contrave) for the management of obesity

Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prolonged release (...) naltrexone and bupropion (Contrave) for the management of obesity. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Naltrexones; Narcotic Antagonists; Obesity; Weight Loss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

2013 Health Technology Assessment (HTA) Database.

4. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of varenicline compared with bupropion or no aid for smoking cessation in Finland. The authors concluded that varenicline was more effective and resulted in cost savings

2010 NHS Economic Evaluation Database.

5. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. (PubMed)

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Substantial concerns have been raised about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion. Their efficacy relative to nicotine patch largely relies on indirect comparisons, and there is limited information on safety and efficacy in smokers (...) with psychiatric disorders. We compared the relative neuropsychiatric safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without psychiatric disorders.We did a randomised, double-blind, triple-dummy, placebo-controlled and active-controlled (nicotine patch; 21 mg per day with taper) trial of varenicline (1 mg twice a day) and bupropion (150 mg twice a day) for 12 weeks with 12-week non-treatment follow-up done at 140 centres (clinical trial centres

2016 Lancet (London, England)

6. Naltrexone?bupropion for managing overweight and obesity

Naltrexone?bupropion for managing overweight and obesity Naltre Naltrex xone–bupropion for managing one–bupropion for managing o ov verweight and obesity erweight and obesity T echnology appraisal guidance Published: 12 December 2017 nice.org.uk/guidance/ta494 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naltrexone–bupropion for managing overweight and obesity (TA494) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 The technology 5 3 Committee discussion 6

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

7. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.1; Status: 30.05.2011). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression 30.05.2011 Institute for Quality and Efficiency in Health Care (IQWiG) Version 1.1 - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal

2011 Institute for Quality and Efficiency in Healthcare (IQWiG)

8. Concurrent Bupropion / Varenicline for Smoking Cessation

Concurrent Bupropion / Varenicline for Smoking Cessation Concurrent Bupropion / Varenicline for Smoking Cessation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Concurrent Bupropion / Varenicline (...) varenicline alone or varenicline paired with bupropion. Some participants who would otherwise have failed at their quit smoking attempt could be "rescued" by switching to alternative pharmacotherapies. The proposed study will evaluate the combination treatment against varenicline alone in an adaptive trial design Condition or disease Intervention/treatment Phase Nicotine Dependence Drug: Varenicline Drug: Bupropion Drug: Nicotine patches Drug: Nicotine Inhaler Phase 3 Study Design Go to Layout table

2011 Clinical Trials

9. Mysimba - naltrexone / bupropion

Mysimba - naltrexone / bupropion 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 December 2014 EMA/805547/2015 Committee for Medicinal Products for Human Use (CHMP) Mysimba (naltrexone/bupropion) Procedure No. EMEA/H/C/003687 Applicant: Orexigen Therapeutics Ireland Limited Assessment report for an initial marketing (...) /A Not applicable NCA Noncompartmental analysis NB Naltrexone hydrochloride /Bupropion hydrochloride combination NB16 Naltrexone PR 16 mg/Bupropion PR 360 mg NB32 Naltrexone PR 32 mg/Bupropion PR 360 mg NB48 Naltrexone PR 48 mg/Bupropion PR 360 mg ng Nanogram NICE The National Institute for Health and Care Excellence NNH Number needed to harm NNT Number needed to treat NOS Not otherwise specified OCT2 Organic Cation Transporter-2 PAWC Pharmacologically weighted composite PBO Placebo PCS Potentially clinically

2015 European Medicines Agency - EPARs

10. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (PubMed)

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Despite increasing public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed (...) naltrexone 32 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB32), sustained-release naltrexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB16), or matching placebo twice a day, given orally for 56 weeks. The trial included a 3-week dose escalation. Randomisation was done by use of a centralised, computer-generated, web-based system and was stratified by study centre. Co-primary

2010 Lancet

11. Use of bupropion in patients with depression and the associated risk of seizures: safety

Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Use of bupropion in patients with depression and the associated risk of seizures: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The available evidence of an increased risk of seizures in patients treated with bupropion for depression was inconclusive. This evidence was, however, limited to uncontrolled studies rated as low quality by the authors of the AHRQ

2010 Health Technology Assessment (HTA) Database.

12. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. (PubMed)

Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification. Its safety and efficacy were assessed in four randomized, double-blind, placebo-controlled, 56-week Phase III clinical trials in 4536 adult subjects: COR-1, COR-II, COR-BMOD and COR-DM. All four studies demonstrated (...) statistically significant and clinically meaningful weight loss following up to 52 weeks of treatment with naltrexone/bupropion compared with placebo. The average weight loss from baseline across the four studies was approximately 11-22 lbs (5-9 kg). Results show the efficacy of Contrave for weight loss, as well as significant improvements in cardiometabolic markers. This review focuses on the four studies, their outcomes and the mechanism of action of Contrave.

2016 Future cardiology

13. Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients

Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients Published 7 May 2018 Statement of Advice: naltrexone hydrochloride / bupropion hydrochloride 8mg / 90mg prolonged-release tablets (Mysimba ® ) SMC2086 Orexigen Therapeutics Ireland Limited 6 April 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation naltrexone / bupropion (Mysimba ® ) is not recommended

2018 Scottish Medicines Consortium

14. Bupropion versus other antidepressive agents for depression [Cochrane Protocol]

Bupropion versus other antidepressive agents for depression [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

15. Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2013 Clinical Trials

16. Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months

Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 monthsCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 monthsCommentary Article

2010 Evidence-Based Nursing

17. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD.To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD.In a retrospective cohort study, we used data from 14 350 patients with COPD included (...) in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012. Patients were followed up for 6 months to compare incident cardiovascular (ie, ischaemic heart disease, stroke, heart failure, peripheral vascular disease and cardiac arrhythmias

Full Text available with Trip Pro

2017 EvidenceUpdates

18. Bupropion

Bupropion Top results for bupropion - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for bupropion The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

19. Combination bupropion SR and varenicline for smoking cessation: a systematic review. (PubMed)

Combination bupropion SR and varenicline for smoking cessation: a systematic review. Tobacco is the leading cause of preventable death in the world. Current cessation medications include nicotine replacement therapy (NRT), varenicline, and bupropion, while combination therapy primarily entails NRT with either varenicline or bupropion. However, recent studies have examined varenicline and bupropion in combination.A systematic review assessing the efficacy and safety of combination varenicline (...) and bupropion was conducted.PubMed and Clinicaltrials.gov were searched using terms: "varenicline combination", "bupropion combination", "bupropion AND varenicline", and "bupropion AND varenicline combination smoking cessation", yielding four studies including 1193 total patients.Combination therapy yielded greater efficacy than varenicline monotherapy in two randomized controlled trials and one retrospective outcomes study. One single-arm Phase II trial provided additional efficacy and safety data

2016 The American journal of drug and alcohol abuse

20. Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss

Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss Prescrire IN ENGLISH - Spotlight ''Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss'', 1 October 2015 {1} {1} {1} | | > > > Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss FEATURED REVIEW On average, obese or overweight patients taking naltrexone + bupropion lose only a few kilograms. In contrast, its neuropsychiatric adverse effects are numerous and potentially severe. There is also a risk of hypertension, cardiac arrhythmia and gastrointestinal adverse effects. Full review (4 pages) available for download by subscribers. Abstract Weight loss and its long-term maintenance are mainly based on dietary

2015 Prescrire